Moderna, Inc. logo

Moderna, Inc. (MRNA)

Market Closed
2 Mar, 20:00
NASDAQ (NGS) NASDAQ (NGS)
$
52. 84
-0.73
-1.35%
$
19.49B Market Cap
- P/E Ratio
- Div Yield
9,379,022 Volume
-13.23 Eps
$ 53.57
Previous Close
Day Range
50.45 54.94
Year Range
22.28 55.2
Want to track MRNA and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
MRNA earnings report is expected in 57 days (29 Apr 2026)
Moderna (MRNA) Stock Sinks As Market Gains: Here's Why

Moderna (MRNA) Stock Sinks As Market Gains: Here's Why

The latest trading day saw Moderna (MRNA) settling at $34.45, representing a -1.98% change from its previous close.

Zacks | 1 year ago
Moderna Stock Plummets 17% on 2025 Sales Guidance Slash

Moderna Stock Plummets 17% on 2025 Sales Guidance Slash

The crash in MRNA stock comes after the company slashed its outlook for 2024 and 2025 sales and also announced an expanded cost-cutting initiative.

Zacks | 1 year ago
Watch These Moderna Price Levels as Stock Plummets After Slashing 2025 Revenue Outlook

Watch These Moderna Price Levels as Stock Plummets After Slashing 2025 Revenue Outlook

Moderna (MRNA) shares will likely remain under scrutiny on Tuesday after plunging nearly 17% Monday as the embattled drug maker slashed its 2025 revenue forecast by $1 billion.

Investopedia | 1 year ago
S&P 500 Gains and Losses Today: Moderna Plunges After Big Cut to Sales Forecast

S&P 500 Gains and Losses Today: Moderna Plunges After Big Cut to Sales Forecast

Major U.S. equities indexes were mixed to start a new trading week ahead of inflation data that could provide some clarity on the interest-rate outlook for 2025. Earnings reports from the largest U.S. banks are also set for release this week.

Investopedia | 1 year ago
Moderna slashes 2025 sales forecast, shares sink

Moderna slashes 2025 sales forecast, shares sink

Moderna Inc (NASDAQ:MRNA, ETR:0QF) shares plunged almost 20% after the drugmaker pre-announced fiscal 2024 sales below expectations. The company expects sales of $3 billion to $3.1 billion, below the Street consensus of $3.3 billion.

Proactiveinvestors | 1 year ago
Moderna's $1 Billion Revenue Forecast Cut Sends Stock Plummeting Over 20%

Moderna's $1 Billion Revenue Forecast Cut Sends Stock Plummeting Over 20%

Shares of pharmaceutical giant Moderna (MRNA) plunged Monday after the company cut its 2025 revenue forecast by $1 billion.

Investopedia | 1 year ago
Why Moderna Stock Just Crashed 21%

Why Moderna Stock Just Crashed 21%

Moderna's (MRNA -21.95%) sales are slowing down, and Moderna stock is going down -- a lot.

Fool | 1 year ago
Moderna Stock Heads for Worst Day Ever on Forecast Cut

Moderna Stock Heads for Worst Day Ever on Forecast Cut

Moderna Inc (NASDAQ:MRNA) lowered its 2025 revenue forecast to a range of $1.5 billion to $2.5 billion, marking a $1 billion reduction from previous estimates.

Schaeffersresearch | 1 year ago
Moderna Stock Heads for Worst-Ever Day After Reducing Revenue Forecast

Moderna Stock Heads for Worst-Ever Day After Reducing Revenue Forecast

Moderna Inc (NASDAQ:MRNA) lowered its 2025 revenue forecast to a range of $1.5 billion to $2.5 billion, marking a $1 billion reduction from previous estimates.

Schaeffersresearch | 1 year ago
Cramer's Stop Trading: Moderna

Cramer's Stop Trading: Moderna

CNBC's Jim Cramer explains why he is keeping an eye on shares of Moderna.

Youtube | 1 year ago
Moderna Stock Crashes 21% After Covid Vaccine Maker Slashes 2024-25 Guidance

Moderna Stock Crashes 21% After Covid Vaccine Maker Slashes 2024-25 Guidance

Moderna stock crashed Monday after the firm slashed its outlooks for 2024 and 2025, and announced an expanded cost-cutting initiative. The post Moderna Stock Crashes 21% After Covid Vaccine Maker Slashes 2024-25 Guidance appeared first on Investor's Business Daily.

Investors | 1 year ago
Moderna Expects Lower Annual Sales, Expands Cost-Cutting Initiatives

Moderna Expects Lower Annual Sales, Expands Cost-Cutting Initiatives

Moderna Inc. MRNA stock plunged on Monday after the company announced business updates and progress across its pipeline. Moderna says it enters 2025 with a focus on a prioritized portfolio addressing respiratory viruses, rare diseases, oncology, and latent and other viruses.

Benzinga | 1 year ago
Loading...
Load More